Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Betamethasone phosphat

C22H2CJFO5 378-44-9) see Betamethasone benzoate Betamethasone butyrate propionate Betamethasone dipropionate Betamethasone phosphate Betamethasone valerate... [Pg.2308]

The intrascleral implant is a device that is implanted in the sclera it delivers the drug through the sclera to the intraocular tissues (Fig. 5). Transscleral delivery may be an effective method of achieving therapeutic concentrations of drugs in the posterior segment (24-27). The intrascleral implant that incorporated betamethasone phosphate (BP) successfully delivered the drug to the retina/choroid and vitreous (28). The concentration of BP was maintained at a level that should suppress inflammation in the retina-choroid for more than eight weeks, and did not produce any ocular toxicity. [Pg.178]

Figure 12 Profiles of in vitro release of BP from the implant. The values are shown as mean SD. Abbreviation BP, betamethasone phosphate. Source From Ref. 23. Figure 12 Profiles of in vitro release of BP from the implant. The values are shown as mean SD. Abbreviation BP, betamethasone phosphate. Source From Ref. 23.
Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 2003 44 740-744. [Pg.191]

Loading Negatively Charged Dexamethasone-Phosphate and Betamethasone-Phosphate into a Series of Positively Charged Model Proteins... [Pg.515]

Figure 9.40. Loading profiles for (A) dexamethasone-phosphate and (B) betamethasone-phosphate using the series of Lys (K)/Phe (F)-OTntaining Model proteins x through xiv in Table 5.5. (Reproduced with permission from Urry et al. )... Figure 9.40. Loading profiles for (A) dexamethasone-phosphate and (B) betamethasone-phosphate using the series of Lys (K)/Phe (F)-OTntaining Model proteins x through xiv in Table 5.5. (Reproduced with permission from Urry et al. )...
Ishihara T, Kubota T, Choi T, Takahashi M, Ayano E, Kanazawa H, et al. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int J Pharm 2009 375(1—2) 148—54. [Pg.59]

In our laboratoiy. we have checked the possibility of using Aquacoat. spheres as systems for the controlled release of betamethasone phosphate (BMP) and ttcctaic (BM A), glucocoiticoids used in the treatment of rheumatological diseases. and frequently prescribed in creams for topical use. For example. Fig. 21 (126) show.s that Aquacoat particles can adsorb considerable amounts of BMP. giv ing an isotherm veiy. similar to that normally found in the adsorption of amphiphilic substances. [Pg.452]


See other pages where Betamethasone phosphat is mentioned: [Pg.232]    [Pg.2441]    [Pg.276]    [Pg.232]    [Pg.2441]    [Pg.237]    [Pg.185]    [Pg.515]    [Pg.515]    [Pg.517]    [Pg.517]    [Pg.146]    [Pg.1118]    [Pg.396]    [Pg.510]    [Pg.102]   
See also in sourсe #XX -- [ Pg.232 ]




SEARCH



Betamethasone

Betamethasone dihydrogen phosphate

Betamethasone phosphate

Betamethasone sodium phosphate

© 2024 chempedia.info